ArticleAmerican journal of translational research2025
Clinical and pathological characteristics and prognosis analysis of breast cancer patients stratified by age.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the clinical characteristics of breast cancer patients across different age groups and their impact on prognosis.
methodsA retrospective study was conducted from January 2022 to December 2023, including 105 breast cancer patients. These patients were stratified into three groups: young (<40 years), middle-aged (40-59 years), and elderly (≥60 years).
resultsThe mean age at diagnosis was 52.74 years, with the highest incidence observed in the middle-aged group. Significant differences were found across age groups in histological grade, tumor size, molecular subtype, Ki67, carcinoembryonic antigen (CEA), and carbohydrate antigen 15-3 (CA15-3) (all P<0.05). Disease-free survival (DFS) rates varied significantly across age groups, with differences in histological grade, tumor size, molecular subtype, Ki67, CEA, and CA15-3 levels (
conclusionThe clinical characteristics and prognosis of breast cancer patients vary significantly by age group. Combining age with molecular subtype can optimize risk stratification and provide a valuable reference for individualized treatment and prognosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.